Gram-negative

(redirected from Gram-negative bacterial infections)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
  • adj

Words related to Gram-negative

(of bacteria) being of or relating to a bacterium that does not retain the violet stain used in Gram's method

References in periodicals archive ?
PP-0121, pritoxaximab + setoxaximab, Proteins for Infectious Diseases, PT-4, Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections, RX-05, RXP-873, SB-041, Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections, Shigetec, SLP-0901, SLP-0905, Small Molecule for Gram-Negative Nosocomial Infections, Small Molecule to Inhibit Rns and VirF for Bacterial Infections,
CAZ-AVI (ceftazidime-avibactam) is an investigational antibiotic being developed to treat serious Gram-negative bacterial infections.
A snapshot of the global therapeutic scenario for Gram-Negative Bacterial Infections.
Andrea Kwa reported on 26 patients with multidrug-resistant Gram-negative bacterial infections treated with polymyxin B at Singapore General Hospital.
The drug is currently also being studied in a second complicated skin infection trial (STRAUSS II) targeting both Gram-positive and Gram-negative bacterial infections, including patients with diabetic foot infections; and in phase III clinical trials in nosocomial pneumonia (CHOPIN studies) and in patients hospitalized with community-acquired pneumonia.
About CEFTAZIDIME-AVIBACTAM Ceftazidime-avibactam is an investigational antibiotic being developed to treat serious Gram-negative bacterial infections.
Cubist is developing CXA-201 as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa.
The compound is being developed to treat a broad range of Gram-negative bacterial infections, which are becoming resistant to antibiotics and pose an increasing threat to public health.
With its novel mechanism of action, and potential to be administered both orally and intravenously, we believe GSK '052 has the potential to improve the lives of patients suffering from Gram-negative bacterial infections which have grown increasingly resistant to existing antibiotics.
CXA-201 is being developed as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections in the hospital, including those caused by multi-drug resistant Pseudomonas aeruginosa.
a biopharmaceutical company discovering and developing treatments for life-threatening, multi-drug resistant (MDR) Gram-negative bacterial infections, announced today that the company's board of directors has appointed Kenneth J.
Ceftazidime-avibactam is an investigational antibiotic being developed to treat serious Gram-negative bacterial infections.
NASDAQ: AKAO) associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.
Synereca's novel potentiators have shown the ability to significantly enhance the potency of Colistin, a last-line therapy against serious Gram-Negative bacterial infections, up to 500-fold against both susceptible and multi-drug resistant strains of Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobactericeae species including Klebsiella pneumonia and E.
Achaogen is developing plazomicin, a next-generation aminoglycoside that overcomes common bacterial resistance mechanisms, as an intravenous treatment for serious Gram-negative bacterial infections, including those caused by multi-drug resistant (MDR) Escherichia coli and Klebsiella pneumoniae.
Full browser ?